Table 1.
Demographics of the Participants
| Group | ID | Age | Sex | Days on cART | Days current cART | Current cART | CD4+ T cell nadir/mm3 | %CD4+ T cell nadir | Baseline CD4+ T cells/mm3 | Ending CD4+ T cells/mm3 | Baseline %CD4+ T cell | Ending %CD4+ T cell |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Probiotic | GAN02 | 37 | M | 4,506 | 1,161 | TDF/FTC/ATV/r | 17 | 4.0% | 335 | 343 | 23.9% | 26.4% |
| GAN04 | 42 | M | 1,679 | 449 | TDF/FTC/DRV/r | 77 | N/A | 452 | 494 | 21.5% | 24.7% | |
| GAN07 | 59 | M | 5,186 | 771 | RAL/FTC/NVP | 139 | 19.8% | 449 | 366 | 26.4% | 30.5% | |
| GAN09 | 50 | M | 2,499 | 980 | TDF/FTC/LPV/r | 168 | 8.0% | 377 | 377 | 14.5% | 13.0% | |
| GAN11 | 40 | M | 1,542 | 251 | ABC/DRV/r/TDF/FTC | 18 | 3.5% | 278 | 510 | 25.3% | 30.0% | |
| GAN12 | 45 | M | 3,533 | 306 | TDF/FTC/EFV | N/A | N/A | 571 | 757 | 40.8% | 44.5% | |
| GAN13 | 48 | M | 4,336 | 835 | ABC/3TC/NVP | 191 | N/A | 521 | 622 | 41.4% | 44.4% | |
| GAN15 | 72 | M | 5,087 | 589 | TDF/FTC/ATV/r | 51 | 25.4% | 572 | 505 | 28.6% | 29.7% | |
| GAN17 | 59 | M | 3,029 | 1,128 | ATV/r/RAL | 180 | 18.0% | 517 | 686 | 28.7% | 31.2% | |
| GAN23 | 52 | M | 2,170 | 1,450 | ABC/3TC/FPV/r/NVP | 384 | 24.0% | 818 | 709 | 37.2% | 37.3% | |
| Median | 49 | 3,281 | 803 | 139 | 13.0% | 485 | 508 | 27.5% | 30.3% | |||
| SD | 11 | 1,375 | 395 | 115 | 8.8% | 152 | 150 | 8.6% | 9.4% | |||
| Placebo | GAN01 | 53 | M | 262 | 356 | TDF/FTC/EFV | 374 | 17.8% | 600 | 631 | 25.0% | 28.7% |
| GAN03 | 51 | M | 3,771 | 1,552 | TDF/FTC/EFV | 371 | 23.0% | 644 | 580 | 46.0% | 44.6% | |
| GAN10 | 37 | M | 1,066 | 658 | TDF/FTC/RAL | 252 | 19.4% | 432 | 351 | 27.0% | 19.5% | |
| GAN14 | 52 | M | 4,353 | 460 | ABC/3TC/RTV | N/A | N/A | 416 | 486 | 19.8% | 18.0% | |
| GAN18 | 49 | M | 3,784 | 791 | ABC/3TC/TDF/DRV | 7 | 2.0% | 303 | 325 | 27.5% | 25.0% | |
| GAN21 | 46 | M | 3,957 | 692 | ATV/r/RAL | 194 | 19.4% | 290 | 333 | 24.2% | 23.8% | |
| GAN24 | 51 | F | 1,704 | 794 | ABC/3TC/ATV | 34 | 4.3% | 649 | 963 | 29.5% | 27.5% | |
| Median | 51 | 3,771 | 692 | 223 | 18.6% | 432 | 486 | 27.0% | 25.0% | |||
| SD | 6 | 1,645 | 387 | 159 | 8.8% | 155 | 229 | 8.3% | 8.8% |
TDF, tenofovir; FTC, emtricitabine; ATV, atazanavir; /r, low dose ritonavir; DRV, darunavir; RAL, raltegravir; LPV, lopinavir; ABC, abacavir; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; FPV, fosamprenavir; RTV, ritonavir; NA, not available.